Seth Roberts
New member
Binding and conversion
Whether or not a steroid has "DHT-Like" sides has to do with several things, but the most important two are binding affinity and enzymatic conversion. DHT has higher binding affinity (binds more tightly) to the androgen receptor than testosterone. Therefore, it will bind more tightly to the androgen receptor than testosterone in all tissues that are responsive to androgens (that is, tissues with androgen receptors). One notable exception is skeletal muscle, where DHT is converted by an enzyme into an inactive metabolite. A good example of this is Nandrolone which binds more strongly to the androgen receptor than DHT or testosterone. However, it is not as active in DHT target tissues (those tissues containing 5-alpha reductase) because it is converted by 5-alpha reductase to a less active metabolite. This is why nandrolone has less "DHT-like" effects. There is one caveat -- if one takes a high enough dosage of a steroid with low bindig affinity, it can still become very active at DHT target tisses even if not a DHT derivative. The same is true if one were to take enough nandrolone to overcome the enzymatic capacity of 5-alpha reductase -- then nandrolone would start binding preferentially to androgen receptors in DHT target tissues increasing the "DHT-like" side effects. Finally, if you were to take only testosterone with finasteride you could stil get "DHT-like" effects if one takes high enough doses of test to equate to the net androgen receptor activation in DHT target tissues that would have resulted if finasteride were not used.
Seth
Whether or not a steroid has "DHT-Like" sides has to do with several things, but the most important two are binding affinity and enzymatic conversion. DHT has higher binding affinity (binds more tightly) to the androgen receptor than testosterone. Therefore, it will bind more tightly to the androgen receptor than testosterone in all tissues that are responsive to androgens (that is, tissues with androgen receptors). One notable exception is skeletal muscle, where DHT is converted by an enzyme into an inactive metabolite. A good example of this is Nandrolone which binds more strongly to the androgen receptor than DHT or testosterone. However, it is not as active in DHT target tissues (those tissues containing 5-alpha reductase) because it is converted by 5-alpha reductase to a less active metabolite. This is why nandrolone has less "DHT-like" effects. There is one caveat -- if one takes a high enough dosage of a steroid with low bindig affinity, it can still become very active at DHT target tisses even if not a DHT derivative. The same is true if one were to take enough nandrolone to overcome the enzymatic capacity of 5-alpha reductase -- then nandrolone would start binding preferentially to androgen receptors in DHT target tissues increasing the "DHT-like" side effects. Finally, if you were to take only testosterone with finasteride you could stil get "DHT-like" effects if one takes high enough doses of test to equate to the net androgen receptor activation in DHT target tissues that would have resulted if finasteride were not used.
Seth